Activists cry foul over new HIV drug monopoly
Doctors and aid organisations have called upon the Competition Commission of India and the price regulator to step in to ward off the monopoly over a new HIV drug, dolutegravir, which received the approval of the Indian drug controller last month.

Dolutegravir — sold by GlaxoSmithKline's Viiv Healthcare unit under the Trivicay brand — is considered the best-in-class HIV drug as it reduces virus levels faster and has a high barrier to resistance compared to previous line of drugs.

However, only one Indian drug maker, Emcure, will be allowed to sell the medicine in the Indian private market, because of a licensing agreement with Viiv Healthcare under the Medicine Patent Pool....